FDA Approves Asciminib, Drug With Novel Action in CML
This first-in-class STAMP inhibitor is approved for use in patients with chronic myeloid leukemia who have developed resistance to tyrosine kinase inhibitors.
Source: medscape.com
📰 Specifically Targeting News
Specifically Targeting News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Specifically Targeting. Real-time updates on events, politics, business and more.